Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.18
-0.0550-0.39%
Volume:8.82M
Turnover:125.82M
Market Cap:6.42B
PE:-20.08
High:14.75
Open:14.46
Low:13.95
Close:14.23
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.36
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.72
PE(LYR):-12.96

Loading ...

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Oct 01

Iovance Biotherapeutics Appoints Noah Berkowitz, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
Oct 01

Press Release: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Dow Jones
·
Oct 01

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
Sep 30

Top Midday Gainers

MT Newswires Live
·
Sep 30

Crude Oil Down 1%; US Job Openings Fall In August

Benzinga Earnings
·
Sep 30

Iovance Biotherapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 29

Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen

TIPRANKS
·
Sep 29

Iovance Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $20 from $9

THOMSON REUTERS
·
Sep 29

Iovance Hits Two-Year High After Raising Annual Revenue Forecast

Reuters
·
Sep 29

Iovance Biotherapeutics rises 25.9%

TIPRANKS
·
Sep 29

Iovance Biotherapeutics Shares Jump 21% After Co Raises FY26 Revenue Forecast

THOMSON REUTERS
·
Sep 29

Iovance Biotherapeutics Stock Gains After Raising FY Revenue Guidance on Demand for Melanoma Treatments

Dow Jones
·
Sep 29

Movement Alert|Iovance Biotherapeutics, Inc. Rises 18.29% in Regular Trading, Full-Year Revenue Guidance Raised Above Market Expectations

Market Focus
·
Sep 29

Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday

MT Newswires Live
·
Sep 29

Movement Alert|Iovance Biotherapeutics, Inc. Rises 8.46% in Pre-Market Trading, Full-Year Revenue Guidance Raised Above Market Expectations

Market Focus
·
Sep 29

GUIDANCE: (IOVA) Iovance Biotherapeutics Expects 2026 Revenue Range $410M to $420M, vs. FactSet Est of $402.8M

MT Newswires Live
·
Sep 29

Iovance Raises FY 2026 Total Revenue Guidance to $410 Million-$420 Million

Reuters
·
Sep 29

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

THOMSON REUTERS
·
Sep 29

Iovance Grants Inducement Stock Options for 179,750 Shares at $10.02 Each

Reuters
·
Sep 19